Katharine Ann Wallis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katharine Ann Wallis has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Maria Donald
General Practice Clinical Unit, The University of Queensland, Brisbane, QLD, Australia
5 shared publications - Mark Abie Horowitz
North East London NHS Foundation Trust
5 shared publications - Nicholas Zwar
Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia
5 shared publications - Ian A. Scott
Digital Health and Informatics Directorate Metro South Hospital and Health Service Brisbane Queensland Australia
4 shared publications Joanna Moncrieff
University College London London UK
4 shared publications- Joanna Moncrieff
Division of Psychiatry, University College London, London, UK
4 shared publications
Latest Publications
- 7 November 2026
- Published by SAGE Publications in Journal of Telemedicine and Telecare
Utilisation of diverse healthcare providers: Virtual health service engagement and geographic barriers among Aboriginal and Torres Strait Islander adults with chronic disease
Background: Virtual Health Services (VHS) may improve healthcare access for rural Aboriginal and Torres Strait Islander people, but little is known about whether active engagement is associated with more diverse providers or reduced geographic barriers to primary care. This study examined whether active VHS engagement was associated with provider diversity and moderated geographic distance effects on primary care access. Methods: This cross-sectional analysis included 74 Aboriginal and Torres Strait Islander adults enrolled in the Goondir Health Services VHS program in rural Queensland. VHS status (active versus inactive in the past 2 weeks) was the primary exposure, with outcomes being provider diversity across 27 types and visit frequency to 12 services over 12 months. Negative binomial regression, adjusted for sociodemographic, lifestyle and health factors including chronic disease burden examined VHS associations with provider diversity, and interaction terms tested whether active engagement moderated distance effects on Aboriginal Medical Service (AMS) visits. Results: Of 74 participants, 47 (63.5%) were active VHS users. After covariate adjustment including chronic disease burden, active users utilised significantly more diverse providers, including specialists (IRR=1.78, 95% CI: 1.12–2.82), allied health professionals (IRR=1.60, 95% CI: 1.04–2.48) and overall providers (IRR=1.44, 95% CI: 1.13–1.83). Distance was associated with AMS visit frequency among inactive but not active users (interaction IRR=0.24, 95% CI: 0.07–0.85), suggesting VHS may moderate distance barriers to primary care. Conclusions: Active VHS engagement was independently associated with greater use of diverse providers, potentially offsetting geographic barriers to primary care, warranting larger studies.
- 7 November 2026
- Published by SAGE Publications in Journal of Telemedicine and Telecare
Utilisation of diverse healthcare providers: Virtual health service engagement and geographic barriers among Aboriginal and Torres Strait Islander adults with chronic disease
Background: Virtual Health Services (VHS) may improve healthcare access for rural Aboriginal and Torres Strait Islander people, but little is known about whether active engagement is associated with more diverse providers or reduced geographic barriers to primary care. This study examined whether active VHS engagement was associated with provider diversity and moderated geographic distance effects on primary care access. Methods: This cross-sectional analysis included 74 Aboriginal and Torres Strait Islander adults enrolled in the Goondir Health Services VHS program in rural Queensland. VHS status (active versus inactive in the past 2 weeks) was the primary exposure, with outcomes being provider diversity across 27 types and visit frequency to 12 services over 12 months. Negative binomial regression, adjusted for sociodemographic, lifestyle and health factors including chronic disease burden examined VHS associations with provider diversity, and interaction terms tested whether active engagement moderated distance effects on Aboriginal Medical Service (AMS) visits. Results: Of 74 participants, 47 (63.5%) were active VHS users. After covariate adjustment including chronic disease burden, active users utilised significantly more diverse providers, including specialists (IRR=1.78, 95% CI: 1.12–2.82), allied health professionals (IRR=1.60, 95% CI: 1.04–2.48) and overall providers (IRR=1.44, 95% CI: 1.13–1.83). Distance was associated with AMS visit frequency among inactive but not active users (interaction IRR=0.24, 95% CI: 0.07–0.85), suggesting VHS may moderate distance barriers to primary care. Conclusions: Active VHS engagement was independently associated with greater use of diverse providers, potentially offsetting geographic barriers to primary care, warranting larger studies.
- Open Access
Redressing long-term antidepressant use (RELEASE): Pragmatic cluster randomised controlled trial in general practice
BACKGROUND: Safe and effective antidepressant deprescribing strategies are needed in general practice where most antidepressant prescribing occurs. METHODS: We conducted a pragmatic, cluster-randomised controlled trial in general practice to test invitation to general practitioner (GP) review combined with resources to inform shared decision-making and guide hyperbolic tapering for stopping antidepressants compared to usual care. Adults taking antidepressants for longer than 12 months were recruited from 26 Australian GP practices between March 2023 and November 2024, irrespective of their intention to stop or depression or anxiety symptom scores. The primary outcome was cessation at 12 months. Secondary outcomes included cessation at 6 months, and > 75% dose reduction and depression, anxiety and withdrawal symptom scores at 6 and 12 months. RESULTS: Overall, 483 patients were randomised. Mean age was 50 years; 73% were women; mean duration of antidepressant use was 14.1 years. Cessation at 12 months was observed in 32 of 215 (14.9%) intervention and 16 of 187 (8.6%) usual care patients (odds ratio (OR) = 1.95 [95%CI, 1.00 to 3.81]; p=0.050). Cessation at 6 months was observed in 11.7% intervention vs 4.8% usual care (OR = 2.68; 95%CI, 1.18 to 6.05), and > 75% dose reduction at 12 months in 19.6% intervention vs 9.9% usual care (OR = 2.28; 95%CI, 1.20 to 4.31). Symptom scores were similar between groups. No adverse events were attributable to the intervention. CONCLUSIONS: In general practice, invitation to GP antidepressant review combined with information and guidance on hyperbolic tapering can support cessation or dose reduction without causing adverse effects or relapse. Absolute cessation rates were modest but still meaningful given the high prevalence of long-term antidepressant use. TRIAL REGISTRATION: ANZCT registry identifier, ACTRN12622001379707p. WHAT IS ALREADY KNOWN ON THIS TOPIC: Long-term (>12 months) antidepressant use is common in primary care, despite being potentially unnecessary and associated with increased risk of falls, sexual dysfunction, weight gain and diabetes. Lack of recognition and management of antidepressant withdrawal symptoms and fear of relapse are important drivers of long-term use. Safe and effective antidepressant deprescribing strategies are needed in primary care where most antidepressant prescribing occurs. WHAT THIS STUDY ADDS: The RELEASE intervention comprised invitation to GP antidepressant review combined with patient-centred resources to inform shared decision-making and guide hyperbolic tapering. The intervention increased cessation or dose reduction, without increasing adverse effects including relapse, in a challenging population with mean duration of antidepressant therapy of 14.1 years and no intention to stop.
Open AccessRedressing long-term antidepressant use (RELEASE): Pragmatic cluster randomised controlled trial in general practice
BACKGROUND: Safe and effective antidepressant deprescribing strategies are needed in general practice where most antidepressant prescribing occurs. METHODS: We conducted a pragmatic, cluster-randomised controlled trial in general practice to test invitation to general practitioner (GP) review combined with resources to inform shared decision-making and guide hyperbolic tapering for stopping antidepressants compared to usual care. Adults taking antidepressants for longer than 12 months were recruited from 26 Australian GP practices between March 2023 and November 2024, irrespective of their intention to stop or depression or anxiety symptom scores. The primary outcome was cessation at 12 months. Secondary outcomes included cessation at 6 months, and > 75% dose reduction and depression, anxiety and withdrawal symptom scores at 6 and 12 months. RESULTS: Overall, 483 patients were randomised. Mean age was 50 years; 73% were women; mean duration of antidepressant use was 14.1 years. Cessation at 12 months was observed in 32 of 215 (14.9%) intervention and 16 of 187 (8.6%) usual care patients (odds ratio (OR) = 1.95 [95%CI, 1.00 to 3.81]; p=0.050). Cessation at 6 months was observed in 11.7% intervention vs 4.8% usual care (OR = 2.68; 95%CI, 1.18 to 6.05), and > 75% dose reduction at 12 months in 19.6% intervention vs 9.9% usual care (OR = 2.28; 95%CI, 1.20 to 4.31). Symptom scores were similar between groups. No adverse events were attributable to the intervention. CONCLUSIONS: In general practice, invitation to GP antidepressant review combined with information and guidance on hyperbolic tapering can support cessation or dose reduction without causing adverse effects or relapse. Absolute cessation rates were modest but still meaningful given the high prevalence of long-term antidepressant use. TRIAL REGISTRATION: ANZCT registry identifier, ACTRN12622001379707p. WHAT IS ALREADY KNOWN ON THIS TOPIC: Long-term (>12 months) antidepressant use is common in primary care, despite being potentially unnecessary and associated with increased risk of falls, sexual dysfunction, weight gain and diabetes. Lack of recognition and management of antidepressant withdrawal symptoms and fear of relapse are important drivers of long-term use. Safe and effective antidepressant deprescribing strategies are needed in primary care where most antidepressant prescribing occurs. WHAT THIS STUDY ADDS: The RELEASE intervention comprised invitation to GP antidepressant review combined with patient-centred resources to inform shared decision-making and guide hyperbolic tapering. The intervention increased cessation or dose reduction, without increasing adverse effects including relapse, in a challenging population with mean duration of antidepressant therapy of 14.1 years and no intention to stop.
- Open Access
- 18 August 2026
- Published by Center for Open Science in PsyArXiv
Long-term antidepressant use and outcomes in adults: A systematic review
Aims: This is the first study to systematically review the evidence for the outcomes (adverse or beneficial) associated with long-term (>12 months) antidepressant use in adults (18 years or over). Millions of people are taking antidepressants long-term, yet without evidence for the associated outcomes are unable to make an informed choice about whether to continue or attempt stopping. Methods: We searched MEDLINE, Embase, PsycINFO, CINAHL, Scopus and Cochrane Library databases from inception to January 5, 2026, and conducted backward citation search. Eligible studies were randomised controlled trials and observational studies involving adults taking an antidepressant long-term (>12 months) for any indication and a comparator, excluding discontinuation studies (because of the problem of confounding by withdrawal effects). Two reviewers independently extracted data and assessed quality using the Quality Assessment Tool for Quantitative Studies developed by the Effective Public Health Practice Project. Results were reported using a narrative synthesis approach. Results: Forty-eight studies, mostly of weak- or moderate-quality, met inclusion criteria. Four weak-quality studies investigated mental health symptoms, including three RCT-extension studies investigating depressive symptoms with inconsistent findings. Forty-four observational studies examined eight other outcome domains: diabetes, weight and glucose homeostasis; dementia and cognitive performance; cancer; eye conditions; self-reported emotional, interpersonal and biological effects; functional limitation, falls and fracture in older people; Parkinson’s disease and levodopa-induced dyskinesia in people with Parkinson’s disease; and all-cause mortality and suicide. There is evidence that long-term antidepressant use is associated with diabetes onset and weight gain. Evidence across the remaining outcome domains was sparse, inconsistent and generally insufficient to support firm conclusions. There were no studies investigating long-term antidepressant use and broader outcomes such as quality of life, occupational functioning, cost-effectiveness or healthcare utilisation. Conclusions: This review exposes the lack of high-quality evidence for long-term antidepressant use, calling into question justification for the high and rising prevalence of long-term use internationally and highlighting the challenge of informed decision-making. Importantly the evidence for mental health symptoms, the primary clinical indication for these medicines, is sparse and inconsistent. Review findings suggest the need for regular antidepressant monitoring which includes assessment of weight and diabetes risk. High-quality research is needed to clarify the benefits and harms of both continuing antidepressants long-term and stopping long-term antidepressants to inform clinical care and enable people to make informed choices. Systematic review registration: PROSPERO: CRD42023446361
- 18 August 2026
- Published by Center for Open Science in PsyArXiv
Open AccessLong-term antidepressant use and outcomes in adults: A systematic review
Aims: This is the first study to systematically review the evidence for the outcomes (adverse or beneficial) associated with long-term (>12 months) antidepressant use in adults (18 years or over). Millions of people are taking antidepressants long-term, yet without evidence for the associated outcomes are unable to make an informed choice about whether to continue or attempt stopping. Methods: We searched MEDLINE, Embase, PsycINFO, CINAHL, Scopus and Cochrane Library databases from inception to January 5, 2026, and conducted backward citation search. Eligible studies were randomised controlled trials and observational studies involving adults taking an antidepressant long-term (>12 months) for any indication and a comparator, excluding discontinuation studies (because of the problem of confounding by withdrawal effects). Two reviewers independently extracted data and assessed quality using the Quality Assessment Tool for Quantitative Studies developed by the Effective Public Health Practice Project. Results were reported using a narrative synthesis approach. Results: Forty-eight studies, mostly of weak- or moderate-quality, met inclusion criteria. Four weak-quality studies investigated mental health symptoms, including three RCT-extension studies investigating depressive symptoms with inconsistent findings. Forty-four observational studies examined eight other outcome domains: diabetes, weight and glucose homeostasis; dementia and cognitive performance; cancer; eye conditions; self-reported emotional, interpersonal and biological effects; functional limitation, falls and fracture in older people; Parkinson’s disease and levodopa-induced dyskinesia in people with Parkinson’s disease; and all-cause mortality and suicide. There is evidence that long-term antidepressant use is associated with diabetes onset and weight gain. Evidence across the remaining outcome domains was sparse, inconsistent and generally insufficient to support firm conclusions. There were no studies investigating long-term antidepressant use and broader outcomes such as quality of life, occupational functioning, cost-effectiveness or healthcare utilisation. Conclusions: This review exposes the lack of high-quality evidence for long-term antidepressant use, calling into question justification for the high and rising prevalence of long-term use internationally and highlighting the challenge of informed decision-making. Importantly the evidence for mental health symptoms, the primary clinical indication for these medicines, is sparse and inconsistent. Review findings suggest the need for regular antidepressant monitoring which includes assessment of weight and diabetes risk. High-quality research is needed to clarify the benefits and harms of both continuing antidepressants long-term and stopping long-term antidepressants to inform clinical care and enable people to make informed choices. Systematic review registration: PROSPERO: CRD42023446361
- 3 August 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (8)
Antidepressants at the threshold: what is really driving prescribing around dementia diagnosis?
- 3 August 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (8)
Antidepressants at the threshold: what is really driving prescribing around dementia diagnosis?
- Open Access
- 2 June 2026
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 49 (3) , 99-103
Stopping antidepressants: when and how
One in seven Australians takes an antidepressant, with around half taking them long-term (over 12 months). Unnecessarily prolonged antidepressant use should be avoided because of the risk of adverse effects.
- 2 June 2026
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 49 (3) , 99-103
Open AccessStopping antidepressants: when and how
One in seven Australians takes an antidepressant, with around half taking them long-term (over 12 months). Unnecessarily prolonged antidepressant use should be avoided because of the risk of adverse effects.
- 3 March 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (3) , e70154
Antidepressant Prescribing in Australian Primary Care: Time to Reevaluate
Click on the article title to read more.
- 3 March 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (3) , e70154
Antidepressant Prescribing in Australian Primary Care: Time to Reevaluate
Click on the article title to read more.
- Open Access
- 1 October 2025
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 10 (1)
Strengthening integration of pathways into general practice in Australia: a virtual workshop study with stakeholders
Background: There remains an urgent need for more medical graduates choosing general practice to address expanding GP workforce shortages. Priority interventions remain unclear but strengthened integration of medical training pathways into general practice may help. Aim: To explore stakeholder views on ways to strengthen integration of pathways into general practice across the medical education and training pipeline. Design & setting: Participatory research virtual workshop. Participants were purposively sampled to include representation across the Australian medical education and GP training sector. Method: Using a nominal group technique, participants were prompted to generate suggestions in activities that build on known factors, and to discuss proposed new and modified solutions to the GP shortage. Content analysis and synthesis supported iterative review of the categorisation framework until team consensus was reached. Results: Seventeen participants (four workshops) made 145 suggestions, which were refined to 67 proposed interventions. There were three overarching categories: (1) improved equity in pay and status for GP trainees and specialists; (2) increased systemic exposure to general practice and generalism; and (3) clearer pathway options to general practice and generalism. Conclusion: General practice pathways could be strengthened by increased exposure to general practice working conditions and generalism philosophies, along with clearer transitions between different training stages. However, increased equity of resources and the status of general practice within medical specialties were also very important macro factors, beyond education and training alone. Thus, GP pathway interventions require reconfiguration supporting integration into the medical training system to actively value GP healthcare contributions.
- 1 October 2025
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 10 (1)
Open AccessStrengthening integration of pathways into general practice in Australia: a virtual workshop study with stakeholders
Background: There remains an urgent need for more medical graduates choosing general practice to address expanding GP workforce shortages. Priority interventions remain unclear but strengthened integration of medical training pathways into general practice may help. Aim: To explore stakeholder views on ways to strengthen integration of pathways into general practice across the medical education and training pipeline. Design & setting: Participatory research virtual workshop. Participants were purposively sampled to include representation across the Australian medical education and GP training sector. Method: Using a nominal group technique, participants were prompted to generate suggestions in activities that build on known factors, and to discuss proposed new and modified solutions to the GP shortage. Content analysis and synthesis supported iterative review of the categorisation framework until team consensus was reached. Results: Seventeen participants (four workshops) made 145 suggestions, which were refined to 67 proposed interventions. There were three overarching categories: (1) improved equity in pay and status for GP trainees and specialists; (2) increased systemic exposure to general practice and generalism; and (3) clearer pathway options to general practice and generalism. Conclusion: General practice pathways could be strengthened by increased exposure to general practice working conditions and generalism philosophies, along with clearer transitions between different training stages. However, increased equity of resources and the status of general practice within medical specialties were also very important macro factors, beyond education and training alone. Thus, GP pathway interventions require reconfiguration supporting integration into the medical training system to actively value GP healthcare contributions.
- Open Access
- 2 April 2025
- Published by Wiley in Medical Journal of Australia
- Vol. 222 (9) , 430-432
Antidepressant prescribing in Australian primary care: time to reevaluate
- 2 April 2025
- Published by Wiley in Medical Journal of Australia
- Vol. 222 (9) , 430-432
Open AccessAntidepressant prescribing in Australian primary care: time to reevaluate
- Open Access
- 20 February 2025
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 9 (3)
General practice specialty decision making: a system-level Australian qualitative study
Background: Ensuring sufficient supply of GPs is critical for servicing increasing healthcare demands. Heightened by pandemic conditions, chronic shortages of GPs persist globally. While many factors reinforcing the choice of general practice as a specialty are known, system-level understanding of factors that influence GPs’ career decision making during their medical training requires investigation. Aim: To explore the reasons for specialty choice through career selection narratives of recently registered Australian GPs, using a system-level perspective. Design & setting: Semi-structured interviews were selected for in-depth explorations of the rationale for choosing general practice as a specialty. Within Australia, medical specialty training choices are typically made after both university medical education and mandatory 1–2 year pre-vocational (hospital-based) training have been completed. Method: Interviews were conducted online with GPs who had completed all training in the last 10 years. De-identified and verified transcripts underwent participant checking. Deductive framework analysis, using career counselling constructs, and inductive thematic analysis were performed. Results: There were 25 participants. Career counselling constructs provided system-level understanding of GP specialty decision-making processes. Many participants highlighted that there were large gaps in information about a GP career throughout medical training. Overcoming negative medical narratives about general practice was necessary for most in choosing a GP career. However, positive experiences with GP communities or work gave insights into the broad flexibility of their person–specialty fit with general practice. Conclusion: GP work experiences and personal GP connections could counteract prominent negative narratives about GP careers. However, lack of systemic and regular exposure to GPs throughout medical training is a critical barrier that should be addressed through sustained policy and professional interventions.
- 20 February 2025
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 9 (3)
Open AccessGeneral practice specialty decision making: a system-level Australian qualitative study
Background: Ensuring sufficient supply of GPs is critical for servicing increasing healthcare demands. Heightened by pandemic conditions, chronic shortages of GPs persist globally. While many factors reinforcing the choice of general practice as a specialty are known, system-level understanding of factors that influence GPs’ career decision making during their medical training requires investigation. Aim: To explore the reasons for specialty choice through career selection narratives of recently registered Australian GPs, using a system-level perspective. Design & setting: Semi-structured interviews were selected for in-depth explorations of the rationale for choosing general practice as a specialty. Within Australia, medical specialty training choices are typically made after both university medical education and mandatory 1–2 year pre-vocational (hospital-based) training have been completed. Method: Interviews were conducted online with GPs who had completed all training in the last 10 years. De-identified and verified transcripts underwent participant checking. Deductive framework analysis, using career counselling constructs, and inductive thematic analysis were performed. Results: There were 25 participants. Career counselling constructs provided system-level understanding of GP specialty decision-making processes. Many participants highlighted that there were large gaps in information about a GP career throughout medical training. Overcoming negative medical narratives about general practice was necessary for most in choosing a GP career. However, positive experiences with GP communities or work gave insights into the broad flexibility of their person–specialty fit with general practice. Conclusion: GP work experiences and personal GP connections could counteract prominent negative narratives about GP careers. However, lack of systemic and regular exposure to GPs throughout medical training is a critical barrier that should be addressed through sustained policy and professional interventions.
- Open Access
RELEASE: REdressing Long-tErm Antidepressant uSE in adults in general practice (RELEASE): A two-arm parallel-group cluster RCT effectiveness-implementation hybrid type-1 study
The REdressing Long-tErm Antidepressant uSE in general practice (RELEASE) trial is a pragmatic cluster randomized controlled trial (cRCT) that seeks to determine whether a novel multi-strategy intervention that supports safe cessation of long-term antidepressants is superior to Usual Care. 1 Pragmatic trials are designed to determine how well interventions work in clinical practice under everyday conditions. 2 The multi-strategy intervention has two forms, known as RELEASE and RELEASE+. RELEASE for patients includes direct patient education and resources 3 and an invitation to medication review; RELEASE for general practitioners (GPs) includes education, training in the brief intervention (Ask, Advise, Assist) and printable resources via practice management software. RELEASE+ additionally includes for patients links to freely available information online via an App, and for GPs clinical audit and feedback on practice prescribing of antidepressants. Patient directed education material has the potential to support safer prescribing, including in this case improved recognition and management of antidepressant withdrawal symptoms. 4, 5 Brief interventions have the potential to change GP prescribing behaviour. 6 The primary comparison of interest is whether any RELEASE intervention is superior to Usual Care. A secondary comparison will be between the two types of RELEASE interventions (RELEASE and RELEASE+). The purpose of this document is to minimise bias and ensure transparency and internal validity for the findings of the trial, by defining and making publicly available the analysis approach prior to reviewing or analysing trial data. The statistical analysis plan (SAP) will inform analysis and reporting of the main effectiveness findings of the trial. It provides a detailed description of the primary and secondary trial outcomes and the methods for statistical comparison.
Open AccessRELEASE: REdressing Long-tErm Antidepressant uSE in adults in general practice (RELEASE): A two-arm parallel-group cluster RCT effectiveness-implementation hybrid type-1 study
The REdressing Long-tErm Antidepressant uSE in general practice (RELEASE) trial is a pragmatic cluster randomized controlled trial (cRCT) that seeks to determine whether a novel multi-strategy intervention that supports safe cessation of long-term antidepressants is superior to Usual Care. 1 Pragmatic trials are designed to determine how well interventions work in clinical practice under everyday conditions. 2 The multi-strategy intervention has two forms, known as RELEASE and RELEASE+. RELEASE for patients includes direct patient education and resources 3 and an invitation to medication review; RELEASE for general practitioners (GPs) includes education, training in the brief intervention (Ask, Advise, Assist) and printable resources via practice management software. RELEASE+ additionally includes for patients links to freely available information online via an App, and for GPs clinical audit and feedback on practice prescribing of antidepressants. Patient directed education material has the potential to support safer prescribing, including in this case improved recognition and management of antidepressant withdrawal symptoms. 4, 5 Brief interventions have the potential to change GP prescribing behaviour. 6 The primary comparison of interest is whether any RELEASE intervention is superior to Usual Care. A secondary comparison will be between the two types of RELEASE interventions (RELEASE and RELEASE+). The purpose of this document is to minimise bias and ensure transparency and internal validity for the findings of the trial, by defining and making publicly available the analysis approach prior to reviewing or analysing trial data. The statistical analysis plan (SAP) will inform analysis and reporting of the main effectiveness findings of the trial. It provides a detailed description of the primary and secondary trial outcomes and the methods for statistical comparison.